TABLE 3.

Comparative sensitivities of the Pgp3 assay and commercial ELISAs

Patient group and assayNo. of samples from C. trachomatis- positive patientsSensitivity (%) (95% CI)Difference in sensitivity between the Pgp3 assay and the commercial assaya (%) (95% CI)McNemar's P value
All patients
    Pgp335657.9 (52.7-62.9)
    Ani Labsystems35649.2 (44.0-54.3)8.7 (2.9-14.5)0.003
    SeroCT35647.2 (42.1-52.4)10.7 (4.9-16.5)<0.0005
    Medac35644.4 (39.3-49.6)13.5 (7.0-20.0)<0.0005
Femalesb
    Pgp316473.8 (66.5-79.9)
    Ani Labsystems16459.8 (52.1-67.0)14.0 (5.5-22.5)0.001
    SeroCT16455.5 (47.8-62.9)18.3 (10.1-26.5)<0.0005
    Medac16445.7 (38.3-53.4)28.0 (18.9-37.2)<0.0005
Malesb
    Pgp319044.2 (37.3-51.3)
    Ani Labsystems19040.5 (33.8-47.6)3.7 (−4.5-11.8)0.42
    SeroCT19040.0 (33.3-47.1)4.2 (−4.1-12.6)0.36
    Medac19043.7 (36.8-50.8)0.5 (−8.6-9.6)1.00
  • a The sensitivity of the commercial assay was subtracted from that of the Pgp3 assay.

  • b P values for differences in sensitivity on male versus female sera are as follows: for the Pgp3 test, <0.0005; for the Ani Labsystems assay, <0.0005; for the SeroCT assay, 0.004; and for the Medac assay, 0.75.